Abstracts Archive - Page 759 of 2425 - ACR Meeting Abstracts

Abstract Number: 1565 • ACR Convergence 2020
Joint Cartilage Damage Evaluated by Ultrasound in Patients with Systemic Lupus Erythematosus
Takehisa Ogura¹, Ayako Hirata², Yuki Inoue², Takaharu Katagiri², Yuto Takakura² and Hideto Kameda³, ¹Division of Rheumatology, Department of Internal Medicine, Toho University, Meguro-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University, Tokyo, Japan, ³Toho University, Tokyo, Japan
Background/Purpose: Arthritis in systemic lupus erythematosus (SLE) is typically non-erosive, although some patients with SLE show erosive destruction or Jaccoud’s arthropathy. Previously we have confirmed…
Abstract Number: 1566 • ACR Convergence 2020
Onset and Disease Course of Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitor Therapy at a Single Institution
Christina Boutsicaris¹, Angelo Ciliberti², Elizabeth Lockerman¹, Faizah Siddique³ and Rochella Ostrowski¹, ¹Loyola University Medical Center, Maywood, IL, ²Loyola University Medical Center, Oak Park, IL, ³Loyola University Medical Center, Lombard, IL
Background/Purpose: Immune checkpoint inhibitors (ICI) have improved outcomes for many types of cancer, but the therapy is known to cause immune-related adverse events (IRAE). ICI…
Abstract Number: 1567 • ACR Convergence 2020
Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)
Despina Michailidou¹, Ali R Khaki², Guangyu Wang³, Leonidas Diamantopoulos² and Petros Grivas², ¹Division of Rheumatology, University of Washington, Seattle, Washington, Seattle, WA, ²Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA, ³Department of Biostatistics, University of Washington, Seattle, Washington, Seattle, WA
Background/Purpose: Patients with cancer treated with CPI can develop irAEs. Since immune changes may impact blood counts and ratios, we hypothesized that those would be…
Abstract Number: 1568 • ACR Convergence 2020
Impact of the SARS-CoV-2 Pandemic on a Cohort of Patients with Rheumatic Complications of Immune Checkpoint Inhibitors: A Registry Survey Study
Nilasha Ghosh¹, Aidan Tirpack², Caroline Benson³, Gregory Vitone³, Karmela Kim Chan² and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: It is not known whether cancer patients being treated with immune checkpoint inhibitors (ICI) and/or immunosuppression are more vulnerable to SARS-CoV-2 or more apt…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1570 • ACR Convergence 2020
Immune Checkpoint Inhibitor Treatment in Cancer: Immunomodulator Use and Evaluation by Rheumatology
Amy Cunningham-Bussel¹, Jiaqi Wang¹, Lauren C. Prisco², Lily Martin², Lydia Gedmintas¹, Lindsey Macfarlane¹, Nancy Shadick¹, Mark Awad³, Osama Rahma³, Nicole LeBoeuf³, Ellen Gravallese¹ and Jeffrey Sparks¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Dana-Farber Cancer Institute, Boston, MA
Background/Purpose: Immune checkpoint inhibitors (ICI) are used to treat an expanding number of cancers. Many cancer patients treated with ICI develop immune-related adverse events (irAE)…
Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Sang Kim¹, Jean Tayar², Maria Suarez-Almazor³, Huifang Lu⁴, Yang-Zhi Zhao⁵, Margarita Divenko⁵, William Padron⁵, Emma Rodriguez⁵, Sattva Neelapu⁵, Jennifer Wang⁵, Amish Shah⁵, Nizar Tannir⁵, Don Gibbons⁵, Guillermo Garcia-Manero⁵, Hussein Tawbi⁵, Patrick Hwu⁵, Andrew Futreal⁵, Adi Diab⁵ and Roza Nurieva⁵, ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas MD Anderson Cancer Center, Houston, TX, ⁴MD Anderson, Houston, TX, ⁵MD Anderson, Houston
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
Abstract Number: 1572 • ACR Convergence 2020
Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases
Tomohiro Kameda¹, Shusaku Nakashima¹, Masayuki Inoo², Ikuko Onishi², Noriyuki Kurata², Risa Wakiya³, Mai Mahmound Fahmy Mansour¹, Koichi Sugihara¹, Yusuke Ushio¹, Mikiya Kato¹, Hiromi Shimada¹ and Hiroaki Dobashi¹, ¹Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, ²Internal Medicine, Utazu hospital, Ayauta-gun, Kagawa, Japan, ³Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan
Background/Purpose: Lymphoproliferative disorders (LPD) that develop in rheumatoid arthritis (RA) patients treated with MTX (MTX-LPD) is one of the important complications for RA patients. MTX-LPD…
Abstract Number: 1573 • ACR Convergence 2020
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Kevin Lee¹, Carrie Ye² and Shokrollah Elahi³, ¹Internal Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, University of Alberta, Edmonton, AB, Canada, ³Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…
Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Nilasha Ghosh¹, Karmela Kim Chan², Bridget Jivanelli³ and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…
Abstract Number: 1575 • ACR Convergence 2020
CD6 Is a Target for Cancer Immunotherapy
Jeffrey Ruth¹, Mikel Gurrea Rubio², Kalana Athukorala³, Stephanie Rasmussen¹, Weber Daniel¹, Peggy Randon¹, M Asif Amin¹, Phillip Campbell¹, Pei-suen Tsou¹, Yang Mao-Draayer¹, Qi Wu⁴, Matthew Lind¹, Rosemary Gedert¹, Thomas Lanigan¹, Venkateshwar Keshamouni¹, Nora Singer⁵, Feng Lin⁶ and David Fox⁷, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³University of Michigan, Ann Arbor, MN, ⁴University of Michigan, Ann Arbor, ⁵The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…
Abstract Number: 1576 • ACR Convergence 2020
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
Adam Kilian¹, Yu Pei Eugenia Chock², Irvin Huang³, Elizabeth Graef⁴, Laura Upton⁵, Aneka Khilnani⁶, Sonia Silinsky Krupnikova⁷, Ibrahim Almaghlouth⁸, Laura Cappelli⁹, Ruth Fernandez-Ruiz¹⁰, Brittany Frankel³, Jourdan Frankovich¹¹, Carly Harrison¹², Bharat Kumar¹³, Kanika Monga¹⁴, Jorge Rosario Vega¹¹, Namrata Singh¹⁵, Jeffrey Sparks¹⁶, Elaine Sullo⁶, Kristen Young¹⁷, Ali Duarte-Garcia¹⁸, Michael Putman¹⁹, Sindhu Johnson²⁰, Jean Liew³ and Aruni Jayatilleke²¹, ¹George Washington University, Washington, DC, ²Yale School of Medicine, Greenwich, CT, ³University of Washington, Seattle, WA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Georgetown University School of Medicine, Washington, DC, ⁶The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁷The George Washington University School of Medicine and Health Sciences, Rockville, MD, ⁸King Saud University, Riyadh, Saudi Arabia, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰New York University School of Medicine, New York, ¹¹Temple University, Philadelphia, PA, ¹²Lupus Chat, NA, ¹³University of Iowa Hospitals and Clinics, Iowa City, IA, ¹⁴UT Health Rheumatology, HOUSTON, TX, ¹⁵University of Washington, Bellevue, WA, ¹⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁷University of Texas Southwestern Medical Center, Dallas, TX, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Northwestern University, Chicago, IL, ²⁰University of Toronto, Toronto, ON, Canada, ²¹Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Jeffrey Sarazin¹, Ann Impens², Nada Abdulaziz¹, Stacey Anderson³, Leslie Fecher¹, Christopher Lao¹ and Elena Schiopu¹, ¹Michigan Medicine, Ann Arbor, MI, ²Midwestern University, Ann Arbor, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
Abstract Number: 1578 • ACR Convergence 2020
Rituximab Hypersensitivity in Rheumatic and Inflammatory Diseases: Role of Skin Testing
Sravani Penumarty¹, Javier Quintero Betancourt², Eugenio Capitle² and Reena Khianey², ¹Rutgers, Eastvale, CA, ²Rutgers, Newark, NJ
Background/Purpose: Infusion-related reactions have been reported with rituximab, a monoclonal antibody targeting the CD20 antigen on B cells, and may result in discontinuation of the…
Abstract Number: 1579 • ACR Convergence 2020
Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response
Pankti Reid¹, Daniel Olson² and Thomas Gajewski², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Department of Medicine, Section of Hematology Oncology, Chicago
Background/Purpose: High grade immune-related adverse events (irAEs) to cancer immune checkpoint inhibitors (ICI) require considerable immunosuppression (IS) with high-dose steroids and steroid-sparing IS (SSIS) for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].